{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:05:22Z","timestamp":1787799922577,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1097\/md.0000000000010256","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T10:29:19Z","timestamp":1523442559000},"page":"e0256","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus"],"prefix":"10.1097","volume":"97","author":[{"given":"Xiaodan","family":"lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210309","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jjcc.2011.01.011","article-title":"Cardiovascular disease in recent onset diabetes mellitus","volume":"57","author":"Yamagishi","year":"2011","journal-title":"J Cardiol"},{"key":"R2-9-20210309","doi-asserted-by":"crossref","first-page":"33H","DOI":"10.1016\/0002-9149(89)90113-6","article-title":"Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk","volume":"63","author":"Assmann","year":"1989","journal-title":"Am J Cardiol"},{"key":"R3-9-20210309","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00592-005-0177-z","article-title":"The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction","volume":"42","author":"Mancia","year":"2005","journal-title":"Acta Diabetol"},{"key":"R5-9-20210309","first-page":"e46","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"R6-9-20210309","first-page":"236","article-title":"A ten-year prospective study, 1964-1974, of cardiovascular risk factors in men and women from the Glostrup population born in 1914: multivariate analyses","volume":"28","author":"Schroll","year":"1981","journal-title":"Dan Med Bull"},{"key":"R7-9-20210309","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R8-9-20210309","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/HYPERTENSIONAHA.108.119784","article-title":"Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada","volume":"53","author":"Campbell","year":"2009","journal-title":"Hypertension"},{"key":"R9-9-20210309","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"R10-9-20210309","first-page":"S4","article-title":"Executive summary: standards of medical care in diabetes2012.","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"R11-9-20210309","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"R12-9-20210309","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R13-9-20210309","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"R14-9-20210309","first-page":"2108","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension","volume":"34","author":"Taylor","year":"2013","journal-title":"Eur Heart J"},{"key":"R15-9-20210309","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R16-9-20210309","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"R17-9-20210309","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R18-9-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R19-9-20210309","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Lonn","year":"2000","journal-title":"Lancet"},{"key":"R20-9-20210309","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"key":"R21-9-20210309","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/eurheartj\/ehi225","article-title":"The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy","volume":"26","author":"Daly","year":"2005","journal-title":"Eur Heart J"},{"key":"R22-9-20210309","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"R23-9-20210309","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"R24-9-20210309","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R25-9-20210309","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08037050510008823","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE)\u2014major CV events and stroke in subgroups of patients","volume":"14","author":"Trenkwalder","year":"2005","journal-title":"Blood Press"},{"key":"R26-9-20210309","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R27-9-20210309","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"R28-9-20210309","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.6.9.1195","article-title":"ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial","volume":"6","author":"Ogihara","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R29-9-20210309","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-9-20210309","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"R31-9-20210309","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study","volume":"59","author":"Muramatsu","year":"2012","journal-title":"Hypertension"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:01:23Z","timestamp":1620961283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201804130-00009"}},"subtitle":["A PRISMA-compliant systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010256","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}